If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
6 July 2020 The Federal Court of Australia has upheld a patent victory for Indian generic manufacturer Sun Pharma over Mylan in a dispute over cholesterol drug fenofibrate.
2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
6 July 2020 The Federal Court of Australia has upheld a patent victory for Indian generic manufacturer Sun Pharma over Mylan in a dispute over cholesterol drug fenofibrate.
2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
6 July 2020 The Federal Court of Australia has upheld a patent victory for Indian generic manufacturer Sun Pharma over Mylan in a dispute over cholesterol drug fenofibrate.
2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
